ROIV$28.94
$29.5
Chart
Performance
Key Stats
AI ROIV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyRoivant Sciences exhibits a mixed investment profile. While its long-term growth potential in biopharmaceuticals is promising, current financial performance and technical indicators suggest a cautious approach. Investors should monitor upcoming clinical trial results and regulatory approvals.
Thematic
Roivant Sciences operates within the biopharmaceutical sector, focusing on innovative drug development. Key thematic drivers include advancements in precision medicine, the growing burden of chronic diseases, and the increasing demand for novel therapies in areas like immunology and oncology.
Fundamental
Roivant Sciences demonstrates a mixed financial profile. While it has significant cash reserves, it consistently reports negative earnings and free cash flow, typical for a clinical-stage biopharmaceutical company. Valuation metrics are challenging to interpret due to the absence of consistent profitability.
Technical
The stock is trading below its key moving averages and indicators suggest a bearish short-term trend. Support levels are being tested, and momentum oscillators are leaning towards negative sentiment. A potential short-term bounce is possible, but the overall trend is not strongly bullish.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 80 |
| Market Need for Therapies | 85 |
| Biotech Sector Growth | 70 |
| Technological Advancements | 70 |
| Regulatory Environment | 60 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 10 |
| Growth | 30 |
| Balance Sheet Health | 90 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Short-term Oscillators | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive EPS Surprises
The company has delivered several positive Earnings Per Share (EPS) surprises, notably in Q1 2025 (181.73%) and Q3 2024 (146.15%), indicating better-than-expected profitability in those periods.
Attractive Trailing P/E Ratio
The trailing Price-to-Earnings (P/E) ratio of -28.9 (TTM) combined with positive net income in 2024 (PE of 1.8) suggests potential undervaluation for the most recent full fiscal year, especially compared to prior periods which showed losses.
Bearish Points (8)
Inconsistent EPS Performance
While some quarters show positive EPS surprises, the company has also reported negative EPS surprises (e.g., Q4 2024 at -20.98%, Q3 2023 at -26.76%), indicating volatility and unpredictability in earnings.
Negative Trailing P/E and High P/S
The trailing P/E ratio is negative (TTM: -28.9) due to losses, and the Price-to-Sales (P/S) ratio (TTM: 367.3) is very high, suggesting the current market valuation is not supported by recent earnings and is based on future expectations.
Calendar
August 2025
6
Next Earnings Date
H: $-0.18
A: $-0.23
L: $-0.29
H: 15.00M
A: 7.23M
L: 1.78M
Profile
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.
Seasonals
Price Target
17.00 USD
The 39 analysts offering 1 year price forecasts for ROIV have a max estimate of 22.00 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Operates with a similar decentralized, disease-focused R&D model to Roivant's 'Vant' structure, developing multiple programs across various therapeutic areas simultaneously.
Weight: 90
Key strategic partner and acquirer of several Roivant 'Vant' companies (e.g., Myovant), indicating deep operational and financial ties.
Weight: 85
Focuses on acquiring pharmaceutical royalties and financing drug development, which aligns with Roivant's asset-centric approach to de-risking drug candidates.
Weight: 82
Operates a similar decentralized R&D model, focusing on multiple distinct drug programs under one corporate umbrella, aiming to de-risk development, conceptually similar to Roivant's 'Vant' strategy.